BioXcel Therapeutics completes patient enrollment in Phase 2 trial of BXCL701

BioXcel Therapeutics (BTAI) announced the completion of patient enrollment in the safety lead-in portion of the investigator-sponsored Phase 2 trial of BXCL701 in combination with KEYTRUDA in previously treated metastatic pancreatic ductal adenocarcinoma, PDAC. BioXcel Therapeutics, through its OnkosXcel Therapeutics immuno-oncology subsidiary, is collaborating with Georgetown Lombardi’s Dr. Louis Weiner, director of the cancer center, and Dr. Benjamin Weinberg, the study’s principal investigator. BioXcel Therapeutics and Merck & Co. (MRK) are providing BXCL701 and KEYTRUDA for the trial, respectively. “Pancreatic cancer represents a significant unmet medical need, ranking as the third-leading cause of cancer deaths, yet remains an exceptionally difficult cancer to treat. No novel therapies have emerged in decades, and overall survival for advanced disease has not improved in over 10 years,” said Dr. Weiner. “Building on results from the preclinical work conducted in our lab, we are excited to evaluate BXCL701 in this important trial as a potential treatment for advanced pancreatic cancer.”